MicroStockProfit.com releases investment report featuring Cardium Therapeutics

MicroStockProfit.com announces an investment report featuring Cardium Therapeutics Inc. (AMEX:CXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/ads/CXM

Cardium Therapeutics Inc. (CXM) focuses on the acquisition and development of biomedical product opportunities and businesses that have the potential to address unmet medical needs and definable pathways to partnering, commercialization and other monetizations. Its investment portfolio includes the Tissue Repair Company and Cardium Biologics, which are medical technology companies primarily focused on the development of therapeutic products for wound healing, bone repair and cardiovascular indications. In July 2009, the Company completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company's biomedical investment portfolio.

Message Board Search for CXM: http://www.boardcentral.com/boards/CXM

In the report, the analyst notes:

"Consistent with its long-term strategy, CXM has stated that it intends to consider various corporate development transactions designed to place its product candidates into larger organizations or with partners having existing commercialization, sales and marketing resources, and a need for innovative products."

"In its report last month, CXM announced its agreement with bioRASI, an international contract research organization, to assist the Company in the evaluation of Generx clinical development opportunities within major newly-industrializing markets in Eastern Europe, Asia and Latin America, for patients with chronic coronary artery disease who are either not optimal candidates for or do not have access to costly angioplasty/stenting or cardiac bypass surgery procedures."